Paxxet

/ Unipharm

One tablet daily in the morning with meal.
See prescribing information for full details.

Depressive disorders, generalized anxiety disorder, panic disorder with or without agoraphobia, social phobia, posttraumatic stress disorder, obsessive compulsive disorder.

Hypersensitivity to paroxetine or one of the other constituents. Must not be taken concurrently with serotonin precursors (L-tryptophan, oxitriptan). Should not be used in combination with thioridazine. Must not be taken in combination with MAO inhibitors or within two weeks after termination of treatment with MAO inhibitors, after which treatment with Paxxet should be commenced with caution and the dosage increased gradually. Treatment with MAO inhibitors must not be commenced within two weeks after termination of treatment with Paxxet.

Renal or hepatic impairment: Dosage should be low. While Paxxet is to be administered simultaneously with enzyme inhibitor (e.g. cimetidine), the use of a dose in the lower part of the dosage range should be considered. The duration of therapy should be determined by the course of the illness. In the treatment of PTSD and GAD, the physicians should periodically reevaluate long-term benefit. Should not be administered to children or adolescents less than 18 years old. Use with caution in patients with history of manic episodes and in patients with epilepsy. If seizures occur, the product should be discontinued. Use with caution in patients already receiving neuroleptics, patients undergoing electroconvulsive therapy, patients with narrow-angle glaucoma, patients with history of cardiac disease, patients concomitantly treated with drugs which increase bleeding risk. Patients with severe renal and hepatic insufficiency should only be treated under close medical supervision.
See prescribing information for full details.

Nausea, somnolence, sweating, headache, tremor, asthenia, sleep disturbance, dry mouth, sexual dysfunction, isolated cases of priapism, diarrhea, constipation, dizziness, insomnia. Abrupt discontinuation may lead to symptoms such as dizziness, sensory disturbances, sleep disturbances, agitatation or anxiety, nausea and sweating.

MAOIs, tryptophan, lithium, phenytoin, other anticonvulsants. Drugs affecting liver enzymes, alcohol.